Aridis Pharmaceuticals Inc ARDS

CryptoFundManager Premium

ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19. And the Market Cap is only...

CryptoFundManager Premium

ARDS Aridis Pharmaceuticals received a grant award from the Bill & Melinda Gates Foundation to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2. Aridis Pharmaceuticals is a stock with a mk cap of only 28.249Mil. Before Aridis, Bill & Melinda Gates Foundation...

Rocky88888888888 Premium

H.C. Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business Interview LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on...

CryptoFundManager Premium

Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell. Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail. AstraZeneca PLC (AZN) has a stake in this company. CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune. Aridis Pharmaceuticals can be a potential...

CryptoFundManager Premium

Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Aridis Pharmaceuticals Inc 's monoclonal...

CryptoFundManager Premium

The chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon! Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class...

CryptoFundManager Premium

Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants...

DigitalData

All, I would take a look at ARDS new all time low, news comiong soon on it. No real negative news just short selling due to no news. 7M float makes it an easy hold. Analysts put this way above current PT. I would enter soon maybe wait till next week, and scale in and definitely 10000% like always stop loss. Tip: Always use a market stop loss. I can't tell you...

JibasJr Premium

Order values as shown

LeeStock

do not buy at this time.